Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation

A randomized, open-label study

Yun Fan Liaw, Maria Raptopoulou-Gigi, Hugo Cheinquer, Shiv Kumar Sarin, Tawesak Tanwandee, Nancy Leung, Cheng Yuan Peng, Robert P. Myers, Robert S. Brown, Lennox J Jeffers, Naoky Tsai, Jolanta Bialkowska, Shijie Tang, Suzanne Beebe, Elizabeth Cooney

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization. Subjects were positive or negative for hepatitis B e antigen and experienced or naive for treatment with nucleos(t)ide analogues. The primary efficacy endpoint was the mean reduction in serum hepatitis B virus (HBV) DNA, as determined by polymerase chain reaction, at week 24, adjusted for baseline HBV DNA and lamivudine resistance status by linear regression analysis. Entecavir demonstrated superiority to adefovir for this endpoint (treatment difference 1.74 log10 copies/mL [95% confidence interval -2.30, -1.18]; P < 0.0001). The entecavir group showed a greater change from baseline in HBV DNA at all time points through week 48 and a higher proportion of subjects who achieved HBV DNA < 300 copies/mL at weeks 24 (entecavir 49%; adefovir 16%; P < 0.0001) and 48 (entecavir 57%; adefovir 20%; P < 0.0001). Approximately two-thirds of subjects in both groups showed improvement/stabilization in Child-Turcotte-Pugh status. Model for End-Stage Liver Disease score change at week 48 was -2.6 for entecavir and -1.7 for adefovir. Adverse event rates were comparable between groups. Cumulative hepatocellular carcinoma rates were 12% for entecavir and 20% for adefovir. Cumulative death rates were 23% for entecavir and 33% for adefovir. Week 24 mortality rates were 12% for both groups. Conclusion: Entecavir demonstrated superior virologic efficacy to adefovir in a population of patients with chronic hepatitis B who had hepatic decompensation. Biochemical and clinical benefits were also demonstrated. Entecavir was well tolerated, and early mortality rates were consistent with rates observed in similar populations treated with lamivudine.

Original languageEnglish
Pages (from-to)91-100
Number of pages10
JournalHepatology
Volume54
Issue number1
DOIs
StatePublished - Jul 1 2011
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Safety
Liver
Hepatitis B virus
Lamivudine
DNA
Mortality
adefovir
entecavir
End Stage Liver Disease
Hepatitis B e Antigens
Random Allocation
Population
Hepatocellular Carcinoma
Linear Models
Therapeutics
Regression Analysis
Confidence Intervals
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hepatology

Cite this

Liaw, Y. F., Raptopoulou-Gigi, M., Cheinquer, H., Sarin, S. K., Tanwandee, T., Leung, N., ... Cooney, E. (2011). Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology, 54(1), 91-100. https://doi.org/10.1002/hep.24361

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation : A randomized, open-label study. / Liaw, Yun Fan; Raptopoulou-Gigi, Maria; Cheinquer, Hugo; Sarin, Shiv Kumar; Tanwandee, Tawesak; Leung, Nancy; Peng, Cheng Yuan; Myers, Robert P.; Brown, Robert S.; Jeffers, Lennox J; Tsai, Naoky; Bialkowska, Jolanta; Tang, Shijie; Beebe, Suzanne; Cooney, Elizabeth.

In: Hepatology, Vol. 54, No. 1, 01.07.2011, p. 91-100.

Research output: Contribution to journalArticle

Liaw, YF, Raptopoulou-Gigi, M, Cheinquer, H, Sarin, SK, Tanwandee, T, Leung, N, Peng, CY, Myers, RP, Brown, RS, Jeffers, LJ, Tsai, N, Bialkowska, J, Tang, S, Beebe, S & Cooney, E 2011, 'Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study', Hepatology, vol. 54, no. 1, pp. 91-100. https://doi.org/10.1002/hep.24361
Liaw, Yun Fan ; Raptopoulou-Gigi, Maria ; Cheinquer, Hugo ; Sarin, Shiv Kumar ; Tanwandee, Tawesak ; Leung, Nancy ; Peng, Cheng Yuan ; Myers, Robert P. ; Brown, Robert S. ; Jeffers, Lennox J ; Tsai, Naoky ; Bialkowska, Jolanta ; Tang, Shijie ; Beebe, Suzanne ; Cooney, Elizabeth. / Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation : A randomized, open-label study. In: Hepatology. 2011 ; Vol. 54, No. 1. pp. 91-100.
@article{9974f6cfd0764aad96561453c045f9c1,
title = "Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study",
abstract = "A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization. Subjects were positive or negative for hepatitis B e antigen and experienced or naive for treatment with nucleos(t)ide analogues. The primary efficacy endpoint was the mean reduction in serum hepatitis B virus (HBV) DNA, as determined by polymerase chain reaction, at week 24, adjusted for baseline HBV DNA and lamivudine resistance status by linear regression analysis. Entecavir demonstrated superiority to adefovir for this endpoint (treatment difference 1.74 log10 copies/mL [95{\%} confidence interval -2.30, -1.18]; P < 0.0001). The entecavir group showed a greater change from baseline in HBV DNA at all time points through week 48 and a higher proportion of subjects who achieved HBV DNA < 300 copies/mL at weeks 24 (entecavir 49{\%}; adefovir 16{\%}; P < 0.0001) and 48 (entecavir 57{\%}; adefovir 20{\%}; P < 0.0001). Approximately two-thirds of subjects in both groups showed improvement/stabilization in Child-Turcotte-Pugh status. Model for End-Stage Liver Disease score change at week 48 was -2.6 for entecavir and -1.7 for adefovir. Adverse event rates were comparable between groups. Cumulative hepatocellular carcinoma rates were 12{\%} for entecavir and 20{\%} for adefovir. Cumulative death rates were 23{\%} for entecavir and 33{\%} for adefovir. Week 24 mortality rates were 12{\%} for both groups. Conclusion: Entecavir demonstrated superior virologic efficacy to adefovir in a population of patients with chronic hepatitis B who had hepatic decompensation. Biochemical and clinical benefits were also demonstrated. Entecavir was well tolerated, and early mortality rates were consistent with rates observed in similar populations treated with lamivudine.",
author = "Liaw, {Yun Fan} and Maria Raptopoulou-Gigi and Hugo Cheinquer and Sarin, {Shiv Kumar} and Tawesak Tanwandee and Nancy Leung and Peng, {Cheng Yuan} and Myers, {Robert P.} and Brown, {Robert S.} and Jeffers, {Lennox J} and Naoky Tsai and Jolanta Bialkowska and Shijie Tang and Suzanne Beebe and Elizabeth Cooney",
year = "2011",
month = "7",
day = "1",
doi = "10.1002/hep.24361",
language = "English",
volume = "54",
pages = "91--100",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation

T2 - A randomized, open-label study

AU - Liaw, Yun Fan

AU - Raptopoulou-Gigi, Maria

AU - Cheinquer, Hugo

AU - Sarin, Shiv Kumar

AU - Tanwandee, Tawesak

AU - Leung, Nancy

AU - Peng, Cheng Yuan

AU - Myers, Robert P.

AU - Brown, Robert S.

AU - Jeffers, Lennox J

AU - Tsai, Naoky

AU - Bialkowska, Jolanta

AU - Tang, Shijie

AU - Beebe, Suzanne

AU - Cooney, Elizabeth

PY - 2011/7/1

Y1 - 2011/7/1

N2 - A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization. Subjects were positive or negative for hepatitis B e antigen and experienced or naive for treatment with nucleos(t)ide analogues. The primary efficacy endpoint was the mean reduction in serum hepatitis B virus (HBV) DNA, as determined by polymerase chain reaction, at week 24, adjusted for baseline HBV DNA and lamivudine resistance status by linear regression analysis. Entecavir demonstrated superiority to adefovir for this endpoint (treatment difference 1.74 log10 copies/mL [95% confidence interval -2.30, -1.18]; P < 0.0001). The entecavir group showed a greater change from baseline in HBV DNA at all time points through week 48 and a higher proportion of subjects who achieved HBV DNA < 300 copies/mL at weeks 24 (entecavir 49%; adefovir 16%; P < 0.0001) and 48 (entecavir 57%; adefovir 20%; P < 0.0001). Approximately two-thirds of subjects in both groups showed improvement/stabilization in Child-Turcotte-Pugh status. Model for End-Stage Liver Disease score change at week 48 was -2.6 for entecavir and -1.7 for adefovir. Adverse event rates were comparable between groups. Cumulative hepatocellular carcinoma rates were 12% for entecavir and 20% for adefovir. Cumulative death rates were 23% for entecavir and 33% for adefovir. Week 24 mortality rates were 12% for both groups. Conclusion: Entecavir demonstrated superior virologic efficacy to adefovir in a population of patients with chronic hepatitis B who had hepatic decompensation. Biochemical and clinical benefits were also demonstrated. Entecavir was well tolerated, and early mortality rates were consistent with rates observed in similar populations treated with lamivudine.

AB - A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization. Subjects were positive or negative for hepatitis B e antigen and experienced or naive for treatment with nucleos(t)ide analogues. The primary efficacy endpoint was the mean reduction in serum hepatitis B virus (HBV) DNA, as determined by polymerase chain reaction, at week 24, adjusted for baseline HBV DNA and lamivudine resistance status by linear regression analysis. Entecavir demonstrated superiority to adefovir for this endpoint (treatment difference 1.74 log10 copies/mL [95% confidence interval -2.30, -1.18]; P < 0.0001). The entecavir group showed a greater change from baseline in HBV DNA at all time points through week 48 and a higher proportion of subjects who achieved HBV DNA < 300 copies/mL at weeks 24 (entecavir 49%; adefovir 16%; P < 0.0001) and 48 (entecavir 57%; adefovir 20%; P < 0.0001). Approximately two-thirds of subjects in both groups showed improvement/stabilization in Child-Turcotte-Pugh status. Model for End-Stage Liver Disease score change at week 48 was -2.6 for entecavir and -1.7 for adefovir. Adverse event rates were comparable between groups. Cumulative hepatocellular carcinoma rates were 12% for entecavir and 20% for adefovir. Cumulative death rates were 23% for entecavir and 33% for adefovir. Week 24 mortality rates were 12% for both groups. Conclusion: Entecavir demonstrated superior virologic efficacy to adefovir in a population of patients with chronic hepatitis B who had hepatic decompensation. Biochemical and clinical benefits were also demonstrated. Entecavir was well tolerated, and early mortality rates were consistent with rates observed in similar populations treated with lamivudine.

UR - http://www.scopus.com/inward/record.url?scp=79959551969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959551969&partnerID=8YFLogxK

U2 - 10.1002/hep.24361

DO - 10.1002/hep.24361

M3 - Article

VL - 54

SP - 91

EP - 100

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -